Loading company…
NEORNAT develops immuno-oncology and RNA-based cancer therapies.
Based in Seoul, South Korea, NEORNAT develops macrophage immuno-oncology and RNA regulator-targeted cancer drugs. Founded in 2020, it has programs for liver cancer treatment and diagnosis. In March 2022, it raised KRW 3 billion in Series A funding from Shinhan Capital, DB Financial Investment, DTR Partners, Lab Genomics and Lead Compass Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in